Table 4.
Multivariate Cox proportional hazard models of the risk of ESRD in patients with T2D with clinical predictors and the plasma concentration of a TNF marker stratified according to the presence of proteinuria
| Nonproteinuria | Proteinuria | |||
|---|---|---|---|---|
| HRa (95% CI) | P Value | HRa (95% CI) | P Value | |
| Clinical predictorb | ||||
| HbA1c | 1.56 (0.86, 2.82) | 0.14 | 1.24 (0.96, 1.61) | 0.10 |
| AER | 2.23 (1.11, 4.48) | 0.02 | 2.52 (1.14, 5.56) | 0.02 |
| eGFR | 1.10 (0.72, 1.67) | 0.67 | 1.37 (1.11, 1.69) | 0.004 |
| Individual markerc | ||||
| free TNFα | 2.22 (1.20, 4.12) | 0.01 | 1.21 (0.81, 1.81) | 0.34 |
| total TNFα | 2.53 (1.25, 5.13) | 0.01 | 2.61 (1.42, 4.81) | 0.002 |
| TNFR1 | 7.11 (2.13, 23.69) | 0.0004 | 7.05 (2.23, 22.30) | 0.0018 |
| TNFR2 | 3.82 (1.59, 9.20) | 0.0008 | 5.88 (2.10, 16.43) | 0.0013 |
a
Effect measures are expressed as the HR for a one-quartile increase in the distribution of each covariate except for eGFR, for which it is a one-quartile decrease. Quartile definitions are based on the full cohort.
b
Clinical predictors examined together with TNFR1.
c
Individual TNF markers examined together with all three clinical predictors.